Skip to main content
main-content

Zeitschrift

Investigational New Drugs

Investigational New Drugs 2/2019

Ausgabe 2/2019

Inhaltsverzeichnis ( 22 Artikel )

15.06.2018 | PRECLINICAL STUDIES | Ausgabe 2/2019

Methionine gamma lyase from Clostridium sporogenes increases the anticancer effect of doxorubicin in A549 cells and human cancer xenografts

V. S. Pokrovsky, N. Yu Anisimova, D. Zh Davydov, S. V. Bazhenov, N. V. Bulushova, G. B. Zavilgelsky, V. Y. Kotova, I. V. Manukhov

21.06.2018 | PRECLINICAL STUDIES | Ausgabe 2/2019

Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2

Tomoko Takimoto-Shimomura, Taku Tsukamoto, Saori Maegawa, Yuto Fujibayashi, Yayoi Matsumura-Kimoto, Yoshimi Mizuno, Yoshiaki Chinen, Yuji Shimura, Shinsuke Mizutani, Shigeo Horiike, Masafumi Taniwaki, Tsutomu Kobayashi, Junya Kuroda

22.06.2018 | PRECLINICAL STUDIES | Ausgabe 2/2019

Euphol, a tetracyclic triterpene, from Euphorbia tirucalli induces autophagy and sensitizes temozolomide cytotoxicity on glioblastoma cells

Viviane A. O. Silva, Marcela N. Rosa, Vera Miranda-Gonçalves, Angela M. Costa, Aline Tansini, Adriane F. Evangelista, Olga Martinho, Adriana C. Carloni, Chris Jones, João Paulo Lima, Luiz F. Pianowski, Rui Manuel Reis

22.06.2018 | PRECLINICAL STUDIES | Ausgabe 2/2019

Alteration of benzo(a)pyrene biotransformation by resveratrol in ApcMin/+ mouse model of colon carcinogenesis

Ashley C. Huderson, P. V. Rekha Devi, Mohammad S. Niaz, Samuel E. Adunyah, Aramandla Ramesh

27.06.2018 | PRECLINICAL STUDIES | Ausgabe 2/2019

Inhibition of SHP2 by new compounds induces differential effects on RAS/RAF/ERK and PI3K/AKT pathways in different cancer cell types

Cijo George Vazhappilly, Ekram Saleh, Wafaa Ramadan, Varsha Menon, Aya Mudhafar Al-Azawi, Hamadeh Tarazi, Hajjaj Abdu-Allah, Abdel-Nasser El-Shorbagi, Raafat El-Awady

12.07.2018 | PRECLINICAL STUDIES | Ausgabe 2/2019

The marine natural product Scalarin inhibits the receptor for advanced glycation end products (RAGE) and autophagy in the PANC-1 and MIA PaCa-2 pancreatic cancer cell lines

Esther Amalia Guzmán, Tara Peterson Pitts, Maria Cristina Diaz, Amy Elizabeth Wright

03.08.2018 | PHASE I STUDIES | Ausgabe 2/2019 Open Access

Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

James J. Harding, Todd M. Bauer, Daniel S. W. Tan, Philippe L. Bedard, Jordi Rodon, Toshihiko Doi, Christian Schnell, Varsha Iyer, Fabienne Baffert, Rajkumar Radhakrishnan, Claire Fabre, Dejan Juric

13.08.2018 | PHASE I STUDIES | Ausgabe 2/2019

A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor

Ciara M. Kelly, Alexander N. Shoushtari, Li-Xuan Qin, Sandra P. D’Angelo, Mark A. Dickson, Mrinal M. Gounder, Mary Louise Keohan, Chloe Mcfadyen, Ana Sjoberg, Samuel Singer, Ronald P. DeMatteo, Sinchun Hwang, M. H. Heinemann, Jasmine H. Francis, Cristina R. Antonescu, Ping Chi, William D. Tap

18.08.2018 | PHASE I STUDIES | Ausgabe 2/2019

Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer

Yusuke Chihara, Koji Date, Yoshizumi Takemura, Nobuyo Tamiya, Yoshihito Kohno, Tatsuya Imabayashi, Yoshiko Kaneko, Tadaaki Yamada, Mikio Ueda, Taichiro Arimoto, Junji Uchino, Yoshinobu Iwasaki, Koichi Takayama

22.08.2018 | PHASE I STUDIES | Ausgabe 2/2019 Open Access

A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma

Tycel Phillips, Paul M. Barr, Steven I. Park, Kathryn Kolibaba, Paolo F. Caimi, Saurabh Chhabra, Edwin C. Kingsley, Thomas Boyd, Robert Chen, Anne-Sophie Carret, Elaina M. Gartner, Hong Li, Cindy Yu, David C. Smith

31.08.2018 | PHASE I STUDIES | Ausgabe 2/2019

A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors

Khalid Jazieh, Julian Molina, Jacob Allred, Jun Yin, Joel Reid, Matthew Goetz, Vun-Sin Lim, Scott H. Kaufmann, Alex Adjei

06.09.2018 | PHASE I STUDIES | Ausgabe 2/2019

Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer

Laura W. Goff, Nilofer S. Azad, Stacey Stein, Jennifer G. Whisenant, Tatsuki Koyama, Ulka Vaishampayan, Howard Hochster, Roisin Connolly, Amy Weise, Patricia M. LoRusso, Safia N. Salaria, Wael El-Rifai, Jordan D. Berlin

05.11.2018 | PHASE II STUDIES | Ausgabe 2/2019

Pazopanib with low fat meal (PALM) in advanced renal cell carcinoma

Melissa A. Reimers, Maryann M. Shango, Stephanie Daignault-Newton, Rachel Dedinsky, Danielle Karsies, Shawna Kraft, Liam Riddle, Jeremy A. Felton, Bo Wen, Christina Gersch, James M. Rae, Bruce G. Redman, Ajjai S. Alva

07.11.2018 | PHASE II STUDIES | Ausgabe 2/2019

Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer

Pedro C. Barata, Matthew Cooney, Prateek Mendiratta, Ruby Gupta, Robert Dreicer, Jorge A. Garcia

09.11.2018 | PHASE II STUDIES | Ausgabe 2/2019

A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer

Kei Saito, Hiroyuki Isayama, Yousuke Nakai, Naminatsu Takahara, Kazunaga Ishigaki, Tsuyoshi Takeda, Ryunosuke Hakuta, Tomotaka Saito, Rie Uchino, Takahiro Kishikawa, Tsuyoshi Hamada, Suguru Mizuno, Takashi Sasaki, Hirofumi Kogure, Saburo Matsubara, Natsuyo Yamamoto, Hideaki Ijichi, Keisuke Tateishi, Minoru Tada, Kazuhiko Koike

05.01.2019 | PHASE II STUDIES | Ausgabe 2/2019

Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study

Clinton Yam, Francisco J. Esteva, Miral M. Patel, Akshara S. Raghavendra, Naoto T. Ueno, Stacy L. Moulder, Kenneth R. Hess, Girish S. Shroff, Silvia Hodge, Kimberly H. Koenig, Mariana Chavez Mac Gregor, Robin L. Griner, Sai-Ching J. Yeung, Gabriel N. Hortobagyi, Vicente Valero

08.01.2019 | PHASE II STUDIES | Ausgabe 2/2019

IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study

Tao Lv, Yujie Wang, Dan Ou, Peiyao Liu, Songbing Qin, Lidan Liu, Pengrong Lou, Xiaoshen Wang

01.08.2018 | SHORT REPORT | Ausgabe 2/2019

Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib

Francesco Facchinetti, Letizia Gnetti, Valeria Balestra, Mario Silva, Enrico Maria Silini, Luigi Ventura, Maria Majori, Paola Bordi, Marcello Tiseo

03.08.2018 | SHORT REPORT | Ausgabe 2/2019

Development of apratoxin S10 (Apra S10) as an anti-pancreatic cancer agent and its preliminary evaluation in an orthotopic patient-derived xenograft (PDX) model

Weijing Cai, Ranjala Ratnayake, Michael H. Gerber, Qi-Yin Chen, Yichao Yu, Hartmut Derendorf, Jose G. Trevino, Hendrik Luesch

25.08.2018 | SHORT REPORT | Ausgabe 2/2019

Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma

Charlée Nardin, Sophie Borot, Marie-Astride Beaudoin, Françoise Cattin, Eve Puzenat, Anne-Sophie Gauthier, Franck Schillo, Christophe Borg, François Aubin

10.09.2018 | SHORT REPORT | Ausgabe 2/2019

Novel N-1 substituted fluoroquinolones inhibit human topoisomerase I activity and exhibit anti-proliferative activity

Lisa M. Oppegard, Justine L. Delgado, Chaitanya A. Kulkarni, Tyrell R. Towle, Delaney E. Hart, Bridget P. Williams, Sarah R. C. Lentz, Beverly J. Norris, Craig M. Flory, Robert J. Schumacher, Daryl J. Murry, Robert J. Kerns, Hiroshi Hiasa

10.09.2018 | SHORT REPORT | Ausgabe 2/2019

Identification of differentially expressed genes and signaling pathways using bioinformatics in interstitial lung disease due to tyrosine kinase inhibitors targeting the epidermal growth factor receptor

Yuan Lu, Ang Li, Xiaofeng Lai, Jun Jiang, Lihong Zhang, Zhicheng Zhong, Wen Zhao, Ping Tang, Hu Zhao, Xinling Ren

Aktuelle Ausgaben


 

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise